These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 35632821)
1. Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor. Fonnesu R; Thunuguntla VBSC; Veeramachaneni GK; Bondili JS; La Rocca V; Filipponi C; Spezia PG; Sidoti M; Plicanti E; Quaranta P; Freer G; Pistello M; Mathai ML; Lai M Viruses; 2022 May; 14(5):. PubMed ID: 35632821 [TBL] [Abstract][Full Text] [Related]
2. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation. Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Coronavirus Entry Outlaw VK; Bovier FT; Mears MC; Cajimat MN; Zhu Y; Lin MJ; Addetia A; Lieberman NAP; Peddu V; Xie X; Shi PY; Greninger AL; Gellman SH; Bente DA; Moscona A; Porotto M mBio; 2020 Oct; 11(5):. PubMed ID: 33082259 [TBL] [Abstract][Full Text] [Related]
4. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction. Joseph J; Karthika T; Das VRA; Raj VS Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189 [TBL] [Abstract][Full Text] [Related]
5. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770 [TBL] [Abstract][Full Text] [Related]
6. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19. Gigante A; Aquili A; Farinelli L; Caraffa A; Ronconi G; Enrica Gallenga C; Tetè G; Kritas SK; Conti P Med Hypotheses; 2020 Oct; 143():109856. PubMed ID: 32460208 [TBL] [Abstract][Full Text] [Related]
7. Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses In Vitro. Raghavan PR Biomed Res Int; 2022; 2022():1558860. PubMed ID: 35039793 [TBL] [Abstract][Full Text] [Related]
8. Current Strategies of Antiviral Drug Discovery for COVID-19. Mei M; Tan X Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887 [TBL] [Abstract][Full Text] [Related]
11. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
12. Palmitoylethanolamide counteracts hepatic metabolic inflexibility modulating mitochondrial function and efficiency in diet-induced obese mice. Annunziata C; Lama A; Pirozzi C; Cavaliere G; Trinchese G; Di Guida F; Nitrato Izzo A; Cimmino F; Paciello O; De Biase D; Murru E; Banni S; Calignano A; Mollica MP; Mattace Raso G; Meli R FASEB J; 2020 Jan; 34(1):350-364. PubMed ID: 31914699 [TBL] [Abstract][Full Text] [Related]
13. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634 [TBL] [Abstract][Full Text] [Related]
14. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Costa B; Comelli F; Bettoni I; Colleoni M; Giagnoni G Pain; 2008 Oct; 139(3):541-550. PubMed ID: 18602217 [TBL] [Abstract][Full Text] [Related]
15. The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. Santopolo S; Riccio A; Santoro MG Biochem Biophys Res Commun; 2021 Jan; 538():80-87. PubMed ID: 33303190 [TBL] [Abstract][Full Text] [Related]
16. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. Fantini J; Chahinian H; Yahi N Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156 [TBL] [Abstract][Full Text] [Related]
17. Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation. Roncati L; Lusenti B; Pellati F; Corsi L Prostaglandins Other Lipid Mediat; 2021 Jun; 154():106540. PubMed ID: 33636368 [TBL] [Abstract][Full Text] [Related]
18. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356 [TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP mBio; 2021 Mar; 12(2):. PubMed ID: 33785634 [TBL] [Abstract][Full Text] [Related]